Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India ...

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the ...

The FDA approved a revised label for Eli Lilly’s Amyvid, an imaging drug that helps assess amyloid plaque in Alzheimer’s ...

Find out if Eli Lilly and Co (LLY:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Check out our LLY stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Find the latest Revenue Earnings Per Share data for Eli Lilly and Company Common Stock (LLY) at Nasdaq.com.